Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S1 plus docetaxel in advanced breast cancer
NCT02947061Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Apr 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur + gimeracil + oteracil in breast cancer, sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
tegafur + gimeracil + oteracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02947061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947061.